The project evaluated commercial assays for detecting EGFR mutation in patients with non-small cell lung cancer. The original guidance recommended:

• therascreen EGFR RGQ PCR Kit (CE‑marked, Qiagen)

• cobas EGFR Mutation Test (CE‑marked, Roche Molecular Systems)

• Sanger sequencing of samples with more than 30% tumour cells and therascreen EGFR RGQ PCR Kit for samples with lower tumour cell contents

• Sanger sequencing of samples with more than 30% tumour cells and cobas EGFR Mutation Test for samples with lower tumour cell contents

• Sanger sequencing followed by fragment length analysis and polymerase chain reaction (PCR) of negative samples.

However, there was insufficient evidence to recommend:

• high-resolution melt analysis

• pyrosequencing combined with fragment length analysis

• single-strand conformation polymorphism analysis

• next-generation sequencing

• therascreen EGFR Pyro Kit (CE‑marked, Qiagen)